Document Detail


A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion.
MedLine Citation:
PMID:  9397098     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the abortifacient efficacies of two intravaginally administered misoprostol doses and gemeprost in termination of second-trimester pregnancy. METHODS: Eighty-one women between 12 and 24 weeks' gestation requesting abortion were randomized to receive intravaginally either 100 micrograms of misoprostol at 6-hour intervals (n = 27), 200 micrograms of misoprostol at 12-hour intervals (n = 26), or 1.0 mg of gemeprost at 3-hour intervals (n = 28). The regimen was continued until abortion, or for 36 hours, with assessment of the rate of complete and incomplete abortions as well as side effects within 48 hours from the start of the treatment. RESULTS: The final rates of terminations were 74% in the 100-microgram misoprostol group, 92% in the 200-microgram misoprostol group, and 89% in the gemeprost group. Abortion was complete in 37%, 61%, and 32% in each group, respectively (P = .03, when the 200-microgram misoprostol group was compared with the two other groups). The induction-to-abortion interval was longer (P = .001) in the misoprostol groups (mean 23.1 hours for the 100-microgram and 27.8 hours for the 200-microgram dose) than in the gemeprost group (14.5 hours). There was less pain (P = .01), diarrhea (P = .001), and vomiting (P = .01) in the misoprostol groups than in the gemeprost group. The mean blood loss in the misoprostol groups was lower than in the gemeprost group (P = .001). CONCLUSION: Intravaginal application of 200 micrograms of misoprostol at 12-hour intervals in induction of second-trimester abortion is equally effective to a standard gemeprost regimen. Misoprostol causes fewer side effects and is cheaper and more practical to use.
Authors:
M Nuutila; J Toivonen; O Ylikorkala; E Halmesmäki
Related Documents :
15694088 - Cervical priming with sublingual misoprostol vs. 15-methyl-prostaglandin f2alpha prior ...
2320718 - Congenital malformations, stillbirths, and early mortality among the children of atomic...
2036798 - Embryotoxicity and teratogenicity of dl111-it, an early pregnancy-terminating agent, in...
8968238 - Late selective termination of fetal abnormalities in twin pregnancies: a multicentre re...
9466188 - Pregnancy outcome after assisted fertilization--a short survey.
15232758 - Mode of delivery in pregnancies with premature rupture of membranes at or before term f...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  90     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  1997 Dec 
Date Detail:
Created Date:  1997-12-30     Completed Date:  1997-12-30     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  896-900     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortifacient Agents, Nonsteroidal / administration & dosage*,  adverse effects
Abortion, Induced / methods*
Administration, Intravaginal
Adult
Alprostadil / administration & dosage,  adverse effects,  analogs & derivatives*
Diarrhea / chemically induced
Drug Administration Schedule
Female
Humans
Misoprostol / administration & dosage*,  adverse effects
Nausea / chemically induced
Pain / chemically induced
Pregnancy
Pregnancy Trimester, Second
Time Factors
Chemical
Reg. No./Substance:
0/Abortifacient Agents, Nonsteroidal; 59122-46-2/Misoprostol; 64318-79-2/gemeprost; 745-65-3/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Random protein-creatinine ratio for the quantitation of proteinuria in pregnancy.
Next Document:  Opportunities for prevention of perinatal group B streptococcal disease: a multistate surveillance a...